EFTEKI Trademark

Trademark Overview


On Tuesday, September 1, 2020, a trademark application was filed for EFTEKI with the United States Patent and Trademark Office. The USPTO has given the EFTEKI trademark a serial number of 90151421. The federal status of this trademark filing is REGISTERED as of Tuesday, September 13, 2022. This trademark is owned by ASCENTAGE PHARMA (SUZHOU) CO., LTD.. The EFTEKI trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for dental purposes; Chemical preparations for medical purposes for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Antibiotics; Injectable medicines for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Medicine in tablet form for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Drugs sold in bulk for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Biochemical medicines for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseas...
efteki

General Information


Serial Number90151421
Word MarkEFTEKI
Filing DateTuesday, September 1, 2020
Status700 - REGISTERED
Status DateTuesday, September 13, 2022
Registration Number6841826
Registration DateTuesday, September 13, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 28, 2022

Trademark Statements


Goods and ServicesMedicines for dental purposes; Chemical preparations for medical purposes for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Antibiotics; Injectable medicines for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Medicine in tablet form for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Drugs sold in bulk for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Biochemical medicines for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Antiseptics; Collyrium; Hemorrhoidal suppositories, laxative suppositories, or vaginal suppositories for the prevention and treatment of infections; Medical paster, namely, medical plasters; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes; Medicated sweets; Candy for medical purposes; Dietetic foods adapted for medical purposes; Dietetic beverages adapted for medical purposes; Dietetic preparations adapted for medical purposes; Medicinal oils; Mineral food supplements; Nutritional supplements; Medicines for human purposes for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Bacterial poisons; Pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; Biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Chemical preparations for pharmaceutical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; Radioactive substances for medical purposes; Gases for medical purposes, namely, nitric oxide for medical purposes; Chemical conductors for electrocardiograph electrodes; Semen for artificial insemination; Disinfectants; Solutions for contact lenses; Media for bacteriological cultures; Depuratives for the body; Diagnostic preparations for veterinary purposes; Pesticides; Sanitary napkins; Cotton for medical purposes; Dental abrasives; Diapers for pets

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 6, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameASCENTAGE PHARMA GROUP CORP LIMITED
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressHong Kong 999077
CN

Party NameASCENTAGE PHARMA (SUZHOU) CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSuzhou, Jiangsu 215000
CN

Party NameASCENTAGE PHARMA GROUP CORP LIMITED
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHong Kong 999077
CN

Party NameASCENTAGE PHARMA (SUZHOU) CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSuzhou, Jiangsu 215000
CN

Party NameASCENTAGE PHARMA GROUP CORP LIMITED
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHong Kong 999077
CN

Party NameASCENTAGE PHARMA (SUZHOU) CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSuzhou, Jiangsu 215000
CN

Trademark Events


Event DateEvent Description
Tuesday, September 13, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, September 13, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, June 28, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 28, 2022PUBLISHED FOR OPPOSITION
Wednesday, June 8, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 18, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 17, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 17, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 17, 2022ASSIGNED TO LIE
Thursday, May 12, 2022TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, December 1, 2021NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Wednesday, December 1, 2021INQUIRY TO SUSPENSION E-MAILED
Wednesday, December 1, 2021SUSPENSION INQUIRY WRITTEN
Wednesday, November 24, 2021SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Monday, May 24, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, May 24, 2021LETTER OF SUSPENSION E-MAILED
Monday, May 24, 2021SUSPENSION LETTER WRITTEN
Wednesday, May 12, 2021ASSIGNED TO EXAMINER
Wednesday, March 31, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 30, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 30, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 8, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 8, 2021NON-FINAL ACTION E-MAILED
Friday, January 8, 2021NON-FINAL ACTION WRITTEN
Tuesday, January 5, 2021ASSIGNED TO EXAMINER
Tuesday, October 6, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, September 4, 2020NEW APPLICATION ENTERED IN TRAM